Bollywood actor Ajay Devgn has hit back at the Maharashtra Food and Drug Administration (FDA) over a show cause notice issued to him regarding his elaichi advertisement endorsing Vimal Pan Masala. The notice, issued by the Maharashtra FDA, questioned Devgn’s endorsement of the pan masala brand and demanded its removal from his social media.
- **Notice issued**: The Maharashtra FDA issued a show cause notice to Ajay Devgn regarding his elaichi advertisement.
- **Demand for removal**: The notice demanded the removal of the advertisement from Devgn’s social media platforms.
- **Local impact**: The controversy has raised concerns about the FDA’s handling of advertisements and the impact on local businesses.
Context
The Maharashtra FDA has been cracking down on advertisements that do not comply with its regulations. In this case, the FDA took issue with Devgn’s elaichi advertisement, which it claimed was an endorsement of Vimal Pan Masala. Devgn, however, argued that the FDA acted with a predetermined mindset and failed to disclose relevant information.
Response
Devgn’s petition to the FDA highlights the lack of transparency in the notice. He claimed that the FDA did not provide him with a fair opportunity to respond to the allegations. The controversy has sparked a debate about the FDA’s powers and its handling of advertisements.
“The FDA’s action is prejudging, premeditated, and punitive. They have failed to disclose relevant information and have not given me a fair opportunity to respond,” Devgn said in his petition.
Forward context: The Maharashtra FDA is expected to respond to Devgn’s petition in the coming days. The outcome of the controversy will have a significant impact on the state’s advertising regulations.